Latest News and Press Releases

Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD communityNDS is based on Italfarmaco’s Phase 3 EPIDYS trial...

L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie...

MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief Executive Officer (CEO), effective January 1, 2026. Dr. Di Marco brings over...

Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN,...

Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne muscular dystrophy in Brazil.MILAN, Italy, September 16,...

In total, 11 abstracts on givinostat were accepted for presentation at the Congress, including two for an oral presentation   MILAN, Italy, July 11, 2025 – Italfarmaco S.p.A. announced...

Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progressionDuvyzat is an orally administered treatment for DMD in patients 6...

MILAN, Italy, May 6, 2025 – Italfarmaco S.p.A. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to givinostat for the treatment of patients with...

Recommendation is based on Phase 3 EPIDYS trial data that demonstrated Duvyzat (givinostat) provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular...